Pre-hospital assessment of the role of adrenaline : measuring the effectiveness of drug administration in cardiac arrest (PARAMEDIC-2) : trial protocol

Perkins, Gavin D, Quinn, Tom, Deakin, Charles D, Nolan, Jerry P, Lall, Ranjit, Slowther, Anne-Marie, Cooke, Matthew, Lamb, Sarah E, Petrou, Stavros, Achana, Felix, Finn, Judith, Jacobs, Ian G, Carson, Andrew, Smyth, Mike, Han, Kyee, Byers, Sonia, Rees, Nigel, Whitfield, Richard, Moore, Fionna, Fothergill, Rachael, Stallard, Nigel, Long, John, Hennings, Susie, Horton, Jessica, Kaye, Charlotte and Gates, Simon (2016) Pre-hospital assessment of the role of adrenaline : measuring the effectiveness of drug administration in cardiac arrest (PARAMEDIC-2) : trial protocol. Resuscitation, 108, pp. 75-81. ISSN (print) 0300-9572

Full text available as:
Quinn-T-36132-VoR.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (1MB) | Preview


Despite its use since the 1960s, the safety or effectiveness of adrenaline as a treatment for cardiac arrest has never been comprehensively evaluated in a clinical trial. Although most studies have found that adrenaline increases the chance of return of spontaneous circulation for short periods, many studies found harmful effects on the brain and raise concern that adrenaline may reduce overall survival and/or good neurological outcome. The PARAMEDIC-2 trial seeks to determine if adrenaline is safe and effective in out-of-hospital cardiac arrest. This is a pragmatic, individually randomised, double blind, controlled trial with a parallel economic evaluation. Participants will be eligible if they are in cardiac arrest in the out-of-hospital environment and advanced life support is initiated. Exclusions are cardiac arrest as a result of anaphylaxis or life threatening asthma, and patient known or appearing to be under 16 or pregnant. 8000 participants treated by 5 UK ambulance services will be randomised between December 2014 and August 2017 to adrenaline (intervention) or placebo (control) through opening pre-randomised drug packs. Clinical outcomes are survival to 30 days (primary outcome), hospital discharge, 3, 6 and 12 months, health related quality of life, and neurological and cognitive outcomes (secondary outcomes). Trial registration (ISRCTN73485024).

Item Type: Article
Additional Information: This work was supported by the National Institute for Health Research HTA Programme (project number HTA – 12/127/126).
Research Area: Allied health professions and studies
Nursing and midwifery
Other hospital based clinical subjects
Faculty, School or Research Centre: Faculty of Health, Social Care and Education (until 2017)
Related URLs:
Depositing User: Automatic Import Agent
Date Deposited: 07 Oct 2016 10:48
Last Modified: 29 Jun 2017 08:40

Actions (Repository Editors)

Item Control Page Item Control Page